Vaxcyte Stock Spikes on Competitive Pneumococcal Vaccine Data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vaxcyte's stock jumped after its pneumococcal vaccine held its own against established shots from Pfizer and Merck, per Fierce Biotech's headline.
- BioPharma Dive characterized Vaxcyte's vaccine data as 'near best-case,' while Investor's Business Daily framed the showdown as a small biotech squaring up to Pfizer and Merck in a $7 billion market.
Why it matters: Vaxcyte is a small-cap challenger stepping into a market dominated by Pfizer and Merck, with its stock spiking on competitive vaccine data. If the results hold, Vaxcyte becomes a credible third competitor in a roughly $7 billion pneumococcal vaccine market.
Ask SkimNews
